<span id="tbhtd"></span><span id="tbhtd"></span>
<strike id="tbhtd"></strike>
<span id="tbhtd"><video id="tbhtd"><del id="tbhtd"></del></video></span>
<span id="tbhtd"></span>
<span id="tbhtd"><dl id="tbhtd"></dl></span>
<strike id="tbhtd"><i id="tbhtd"></i></strike>
<span id="tbhtd"><video id="tbhtd"></video></span>


Cirio advises Scandinavian Real Heart on a rights issue


Cirio has advised Scandinavian Real Heart AB (publ) (“Realheart”) in connection with a new issue of shares with pre-emption rights for the company’s shareholders.

Realheart develops a total artificial heart (TAH) for implantation in patients with life-threatening congestive heart failure. Realheart’s TAH has a unique, patented design which consists of a system of four ventricles (two atriums, two ventricles) which provides the possibility of generating a physiologically adapted blood flow that mimics the body's natural circulation. Realheart is listed on Spotlight Stock Market.

Cirio advised Realheart with a team headed by Per Hedman (Life Science and M&A) and Maria Arnoldsson (Capital Markets and Public M&A), together with Oliver Kronberg and Rebecka Tallberg (Capital Markets and Public M&A), Jessika Lagebro (M&A), and Christopher Tehrani and David Leffler (Intellectual Property).

For more information, please contact:
Per Hedman
email hidden; JavaScript is required
+46 76 617 09 21
Maria Arnoldsson
email hidden; JavaScript is required
+46 76 617 09 98